# mRNA

Type: Technology

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/mrna
Canonical HTML page: https://getbiobrief.com/entity/mrna

## Timeline

- **2026-Q4**: Anticipated PDUFA — Expected deadline for the FDA's final approval decision.
- **2026-08-05**: FDA Decision Deadline — The agency faces a deadline to approve or reject the vaccine.
- **2026-06**: Advisory Panel Recommends Approval — An FDA advisory panel votes in favor of approving the vaccine.
- **2026-03-15**: Market Impact — Moderna's valuation remains at roughly 10% of its pandemic-era high amid regulatory uncertainty.
- **2026-02-18**: FDA U-Turn — FDA agrees to review the application after resolving the public dispute.
- **2026-02-18**: Regulatory Reversal — FDA agrees to review the application after Moderna addresses concerns.
- **2026-02-10**: Political Controversy — Reports emerge that the vaccine chief overruled career scientists to block the shot.
- **2026-02-03**: Refusal to File — Senior regulator Vinay Prasad issues a rare letter refusing to review Moderna's flu vaccine application.
- **2026-02**: FDA Issues Refuse-to-File Letter — FDA informs Moderna it will not review the mRNA flu shot application, surprising the company after prior assurances.
- **2026-02**: FDA Accepts Application After Outcry — A little over a week later, the agency reverses its decision after Moderna commits to a confirmatory study.
- **2026-01-10**: Refusal to File — FDA issues a shocking rejection of the application, sparking a public dispute.
- **2026-01**: Refusal to File — FDA issues an RTF citing deficiencies in the initial application.
- **2025-12-01**: Grants Rescinded — The White House rescinds hundreds of millions in mRNA research grants as political rhetoric shifts.
- **2025-11-15**: Initial BLA Submission — Moderna submits its Biologics License Application for mRNA-1010.
- **2025-Q4**: BLA Submission — Moderna submits Biologics License Application for mRNA-1010.

## Recent coverage (4 stories)

### Moderna's mRNA Flu Shot: FDA Decision by Aug 5 Could End 6-Month Regulatory Ordeal
2026-08-01 15:39:40 · Sentiment: Neutral · Impact: 6/10 · Sources: 6

After a shocking FDA refusal-to-file in February and a subsequent advisory panel endorsement, Moderna's experimental mRNA influenza vaccine faces a final decision on August 5. The outcome holds deep implications for the viability of mRNA technology beyond COVID-19 and the future of Moderna's pipeline diversification.
Full story: https://getbiobrief.com/story/moderna-mrna-flu-shot-fda-decision-aug-5

### FDA Regulatory Volatility and Political Shifts Threaten Moderna’s mRNA Pipeline
2026-03-16 00:16:43 · Sentiment: Negative · Impact: 8/10 · Sources: 2

Moderna faces a critical setback after the FDA issued a rare refusal to review its flu vaccine application, signaling a shift in the regulatory and political climate for mRNA technology. This development, coupled with rescinded federal grants and a 90% decline in market value from pandemic peaks, highlights growing friction between the biotech industry and federal oversight.
Full story: https://getbiobrief.com/story/fda-moderna-mrna-regulatory-threat

### FDA Reverses Course, Agrees to Review Moderna’s mRNA Flu Vaccine
2026-02-19 00:58:25 · Sentiment: Positive · Impact: 7/10 · Sources: 2

The FDA has rescinded its initial refusal to file Moderna’s Biologics License Application for its seasonal flu vaccine, mRNA-1010. This rare regulatory pivot clears the path for a formal review of the first mRNA-based influenza shot, a critical milestone for Moderna’s post-pandemic growth strategy.
Full story: https://getbiobrief.com/story/fda-reverses-moderna-flu-vaccine-review

### FDA Reverses Course on Moderna mRNA Flu Shot After Political Dispute
2026-02-18 18:51:48 · Sentiment: Positive · Impact: 8/10 · Sources: 6

Moderna has confirmed that the FDA will officially review its mRNA-based influenza vaccine following a highly publicized regulatory standoff. The reversal comes after reports that the Trump administration's vaccine leadership initially overruled career scientists to block the application.
Full story: https://getbiobrief.com/story/fda-reverses-moderna-flu-shot-review

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.